These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34971603)

  • 1. Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France.
    Roland N; Drouin J; Desplas D; Duranteau L; Cuenot F; Dray-Spira R; Weill A; Zureik M
    Contraception; 2022 Apr; 108():50-55. PubMed ID: 34971603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of coronavirus disease 2019 on contraception use in France.
    Roland N; Drouin J; Desplas D; Duranteau L; Cuenot F; Dray-Spira R; Weill A; Zureik M
    Therapie; 2023; 78(5):593-603. PubMed ID: 36732137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost of contraception in France (FACET study): a cohort study from the French National Healthcare Insurance Database.
    Agostini A; Godard C; Laurendeau C; Benmahmoud A; Lafuma A; Doz M; Lévy-Bachelot L; Gourmelen J; Linet T
    Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():137-143. PubMed ID: 30176517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.
    Agostini A; Godard C; Laurendeau C; Benmahmoud Zoubir A; Lafuma A; Lévy-Bachelot L; Gourmelen J; Linet T
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):421-426. PubMed ID: 30499732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of contraceptive sales before and during the COVID-19 pandemic in Brazil.
    Charles CM; Munezero A; Bahamondes LG; Pacagnella RC
    Eur J Contracept Reprod Health Care; 2022 Apr; 27(2):115-120. PubMed ID: 35156489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
    Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates.
    Turok DK; Jacobson JC; Dermish AI; Simonsen SE; Gurtcheff S; McFadden M; Murphy PA
    Contraception; 2014 Mar; 89(3):222-8. PubMed ID: 24332433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-income women and use of prescribed contraceptives in the context of full health insurance coverage in France, 2019.
    Congy J; Bouyer J; de La Rochebrochard E
    Contraception; 2023 May; 121():109976. PubMed ID: 36758736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study.
    Turok DK; Sanders JN; Thompson IS; Royer PA; Eggebroten J; Gawron LM
    Contraception; 2016 Jun; 93(6):526-32. PubMed ID: 26944863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
    PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
    Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
    Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
    Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contraception for the older woman.
    Guillebaud J
    J Obstet Gynaecol (Lahore); 1985 Jan; 5 Suppl 2():S70-7. PubMed ID: 12268772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.